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Abstract: Multimodality imaging measurements of treatment response are critical for clinical
practice, oncology trials and the evaluation of new treatment modalities. The current
standard for determining treatment response in non-small cell lung cancer (NSCLC) is
based on tumor size using the RECIST criteria. Molecular targeted agents and
immunotherapies often cause morphological change without reduction of tumor size.
Therefore, it is difficult to evaluate therapeutic response by conventional methods.
Radiomics is the study of cancer imaging features that are extracted using machine
learning and other semantic features.  This method can provide comprehensive
information on tumor phenotypes and can be used to assess therapeutic response in
this new age of immunotherapy. Delta radiomics, which evaluates the longitudinal
changes in radiomics features,  shows potential in gauging treatment response in
NSCLC. It is well known that quantitative measurement methods may be subject to
substantial variability due to differences in technical factors and require
standardization. In this review, we describe measurement variability in the evaluation of
non-small cell lung cancer and the emerging role of radiomics.
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Variability in Treatment Response Determination for Non-Small Cell Lung Cancer: 
Improvements using Radiomics” and for giving us a chance to revise the manuscript. 
We tried to do our best in revising the manuscript by accepting your remarkable 
comments thus in enhancing the quality of our study.  
In the revised version of the manuscript, we answered to your queries by assigning a 
number to each query and by answering to each question and thus each number.  
We upload a revised version of the manuscript and corresponding figures to figure 
captions. Our specific responses are as follows: 
 
Memo 1. I do not understand this sentence. Do you mean to say that diameter 
measurement varied by 11% but the volume measurements did not vary at all? 
Please re-write to better highlight what you mean. 
 Done. We have changed the sentence as follows:  
According to a recent review article, although limit of agreement for both manual 
diameter measurements and semi-automated volume measurements lies in the 
same range in terms of absolute percentages, the percentage of lung nodules in 
which an actual inter-reader difference found was with 11% far lower for semi-
automated nodule volume measurements compared to manual diameter 
measurements, where inter-reader variability occurs commonly. 
 
Memo 2. Why wouldn’t this be more information needed to fill a 2D histogram than a 
1D histogram? 
 We have changed the sentence a little bit for clarification. In general, the samples 
in a given bin for a 2D histogram is less than those in an equivalent 1D histogram as 
the voxels need to fill the bins spanning the 2D histogram compared to filling the 1D 
histogram.  
In a hypothetical extreme example, a 5,000 voxel ROI can fill a uniform 10 bin 1D 
histogram with 500 counts in each bin. The same ROI would fill a uniform 10x10 bin 
2D histogram with 50 counts in each bin. 
 
Memo 3. Trim to 80 references. 
 We have reduced 52 references, thus, the total number of 144 references to 92 
references. We have excluded simple references and kept major, repeating 
references. We hope this is acceptable for publication in the journal.  
 
 
Response to Reviewers
Thank you for your attention. We look forward to listening to your favorable review 
results soon. 
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Response Determination for Non-Small Cell Lung Cancer: 
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Revised Manuscript - Annotated Copy
Abstract 
Multimodality imaging measurements of treatment response are critical for clinical 
practice, oncology trials and the evaluation of new treatment modalities. The current 
standard method in the settingfor determining treatment response inof non-small cell 
lung cancer (NSCLC) is based on tumor size using the RECIST criteria. Molecular 
targeted agents and immunotherapies often cause morphological change without 
reduction of tumor size. Therefore, it is difficult to evaluate therapeutic response by 
conventional methods. Radiomics is the study of cancer imaging features that are 
extracted using machine learning and other semantic features.  This method can provide 
comprehensive information on tumor phenotypes and can be used to assess therapeutic 
response in this new age of immunotherapy. Furthermore, although in its early steps, 
Ddelta radiomics, which evaluates the longitudinal changes in radiomics features, 
between interval studies may shows potential in oncology studiesgauging treatment 
response in NSCLC. It is well known that quantitative measurement methods may be 
subject to substantial variability due to differences in technical factors and require 
standardization. In this review, we describe measurement variability in the evaluation of 
non-small cell lung cancer and the emerging role of radiomics. 
 
Key words: Molecular Targeted Therapy; Immunotherapy; Medical oncology; Phenotype; 
Lung cancer response; Image; Radiomics 
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ADC : apparent diffusion coefficient  
AIF : arterial input function 
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SUVbsa : normalization of standardized uptake value for body surface area  
SUVlbm : normalization of standardized uptake value for lean body mass 
TLG : total lesion glycolysis  
TSE : turbo spin-echo 
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1 Introduction 
Assessment of anti-tumor activity of cancer therapies is generally determined by 
an anatomical measurement of tumor burden. Since its first introduction in 2000 and 
subsequent revision in 2009, Response Evaluation Criteria In Solid Tumors (RECIST) has 
served as the reference standard for measuring tumor burden and confirming tumor 
response.1,21 According to RECIST criteria, measurement is the maximal axial (in-plane) 
unidimensional measurement of a tumor’s diameter. However, this conventional tumor 
size analysis is imperfect due to inter and intra reader measurement variability, 
heterogeneous tumor morphology, and different technical parameters at the time of 
scanning.23 All of  these factors contribute to measurement variability, which can lead to 
an erroneous determination of treatment response/progression and  thereby misinform 
inappropriate treatment decisons.2,34,5  
During the past decade, due to an improved understanding of cancer biology, a 
vast collection of targeted molecular therapies have been developed. This has led to a 
paradigm shift in the local and systemic treatment of non-small cell lung cancer (NSCLC). 
While conventional chemotherapy is focused on destroying rapidly dividing tumor cells, 
molecular targeted therapy aims at transmembraneous receptors and intracellular 
molecules that are responsible for the survival and proliferation of tumor cells. Molecular 
targeted therapy has been shown to be effective in tumors with specific genomic driver 
mutations. This, haswhich opened a new era of tumor response evaluation s where the 
limitations of RECIST-based approaches are increasingly being foundnoted.64 Cancer 
immunotherapy with immune-checkpoint blockade attempts for utilization of thehelps to 
activate the cancer pateints own cellular immune system to killfight against the cancer 
cells.7,8 5 It has become increasingly known Ccancer immunotherapy is associated with 
unconventional response patterns that are not may not be accurately characterized by 
conventional response criteria such as the RECIST criteria.7,9,104,5 In addition, 
morphological changes such as tumor necrosis and cavitation without concurrent tumor 
size reduction are frequently observed in the setting of anti-angiogenic therapy.11-132,4 
Formatted: Superscript
Field Code Changed
Formatted: Superscript
Formatted: Superscript
Formatted: Superscript
Formatted: Superscript
Formatted: Superscript
Unfortunately, RECIST criteria do not reflect these changes in the post treatment 
morphology of the target lesion. 
Radiomics is the process of extracting large amounts of advanced quantitative 
information embedded within radiological images. This approach to image analysis aids  
the field of oncology by providing a more quantitative approach for tumor response 
assessment.614 Although state-of-the-art methods have been shown to work well for 
measuring tumor volume, a great deal of variability exists, and radiologists should be 
familiar with the technical variations, benefits, and drawbacks of radiomics regarding 
measurement variability. Furthermore, although computed tomography (CT) continues to 
play an important role, additional imaging modalities such as positron emission 
tomography (PET), magnetic resonance imaging (MRI) dynamic contrast enhanced (DCE) 
perfusion images and MRI diffusion-weighted (DWI) MRI allow for the multiparametric 
assessment of tumor biology (e.g. glucose metabolism, tumor perfusion, and tumor 
hypoxia) of tumor biology.156 Thus, by combining detailed functional and metabolic 
information, these protocols may provide a more comprehensive depiction of the tumor 
microenvironment and may allow for an earlier determination of tumor response. The 
purpose of the review is to focus on the technical issues regarding NSCLC tumor 
measurement variability and how radiomics is emerging for the early assessment of 
tumor response. 
 
2. Technical aspects of measurement 
1) Measuring tumor volume  
A. Segmentation 
Precise NSCLC tumor measurement between interval studies is the current basis 
for tumor response assessment. Although Currently the long axis diameter, a 
unidimensional measurement, remains the standard RECIST criteria for assessment of 
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whether a tumor is growing or shrinking, discordant tumor response between primary 
reviewers and secondary reviewers has been reported.34 In a previous study, according 
tousing RECIST for lung NSCLCcancers, there was a significant difference betweenamong 
readers for unidimensional measurements of tumor size. Probability ofThe 
misclassification rates for progressive disease were 30% and 10% for interobserver and 
intraobserver measurements, respectively.34 The primary reason for this variability is 
related to inter-reader differences in the manual measurements of the primary tumor. 
3,74,16 For instance, in the case of a single unidimensional largest diameter measurement 
for RECIST, each reviewer may measure the tumor at different image slices. As a 
solution to this problem, most radiologists now agree that measuring the entire tumor 
volume is more accurate than a single unidimensional RECIST measurement.17-22 8,9 
Many recent publications have shown that volumetric measurements demonstrate better 
reproducibility and repeatability. According to a recent review article, although limit of 
agreement for both manual diameter measurements and semi-automated volume 
measurements lies in the same range in terms of absolute percentages, the percentage 
of lung nodules in which an actual inter-reader difference found was with 11% far lower 
for semi-automated nodule volume measurements compared to manual diameter 
measurements, where inter-reader variability occurs commonly. Due to more common 
inter-reader variability of manual diameter measurements, the reported percentage of 
lung nodules in which an actual inter-reader difference found was 11% far lower for 
semi-automated nodule volume measurements compared to manual diameter 
measurements.1023 Second, volumetric measurement is more sensitive in detecting even 
small changes than is unidimensional measurement.1124 For example, in a 10 mm 
spherical nodule, a 1 mm increase of unidimensional diameter corresponds to a 10% 
increase in cross-sectional diameter and a 33% increase in volume.1225 Finally, as lung 
CT post-processing computer software is becoming widespread, tumor volumetric 
measurements are gaining in popularity. This has now become the standard for 
oncological trials are beginning as their clinical response endpoint1124. We will now 
discuss the factors aeffecting the variability of tumor volume measurement.1124,26,27 
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Segmentation is the process by which humans (manual segmentation) and 
machines delineate tumor boundaries from the surrounding lung. Generally, the whole 
tumor is selected as the volume of interest (VOI), which is usually feasible, but in certain 
cases may be hampered due to indistinct tumor margins.28,29.13 For example, when lung 
cancer is surrounded by a pathological abnormality such as post-obstructive pneumonia 
or radiation-induced lung injury, the tumor boundary is frequently obscured. Tissue 
reorganization and post radiation therapy, scar formation disrupts accurate tumor 
segmentation, leading to variability in tumor measurement. 
Among various methods of segmentation, automatic and semi-automatic 
methods using volumetric software have been shown to be more reproducible than 
manual segmentation.28,30.13 Although the current “gold standard” is considered to be 
manual segmentation drawn by experts, this method has major drawbacks: (1) it is a 
time-consuming, (2) labor-intensive task and (3) has inter and intra-reader variability. In 
a study comparing manual and semi-automatic segmentation, the radiomics features 
derived from the latter demonstrated significantly higher reproducibility (p=0.0009; 
intra-class correlation coefficient values of 0.85 and 0.77 for semi-automatic 
segmentation and manual segmentation, respectively) and were more robust compared 
to those derived from manual contouring.1431 When comparing repeatability (intra-
algorithm comparisons) and reproducibility (inter-algorithm comparisons) of 
segmentation algorithms, repeatability was significantly higher than the reproducibility 
(p<0.007; average Dice score of 0.95 and 0.81 for repeatability and reproducibility, 
respectively), recommending that the same software be used at all time points in 
longitudinal studies.1532 However, in cases of part-solid adenocarcinomas, which have a 
ground-glass opacity (GGO) component, fully automatic segmentation is also be 
problematic due to the reduced contrast between the GGO component and surrounding 
lung parenchyma.1633 Thus, as of today, for part-solid adenocarcinomas, semi-automatic 
segmentation with tumor margin editing based on subjective decision by an experienced 
expert remains the optimal choice for accurate volumetric assessments of NSCLC (Figure 
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1).34,3517 Likewise, advanced NSCLC lung cancer patients with large tumors having irregular 
margins, heterogenousheterogeneous intra-tumoral texture and surrounding atelectasis or 
effusions often    require semi-automated approach with expert radiologist manual 
editing of the segmentation.921 In the setting of molecular targeted therapy for NSCLC, 
tumor volumes obtained by a semi-automated approach have been shown to be a 
prognostic marker for improved survival ,survival, solidifying its value in this era of precision 
medicine.8,1820,36  
In terms of rapid and accurate tumor segmentation, fully automatic 
segmentation methods based on deep learning may be the solution. Several 
investigators have trained convolutional neural networks and demonstrated that deep 
learning is capable of performing accurate localization and segmentation of tumors in 
multiple organs.37-4019,20 Although most of these articles were based on MRI scans, such 
as brain, prostate, and rectum, deep learning technologies have shown potential to 
improve accuracy and robustness of tumor segmentation. 
Another point that needs to be highlighted is the usage of different vendor 
volumetric software platforms. Studies comparing multiple volumetric software packages 
found considerable variation in nodule volume. This shows that that the results of 
software packages should not be used interchangeably.41-4421,22 Next we discuss the 
impact of technical factors at the time of CT acquisition and CT reconstruction such as 
radiation dose, iterative reconstruction, inspiration, and slice thickness on the variability 
in volumetric measurement. 
 
2) Technical issues according to particular imaging modality 
A. CT  
Chest CT is the modality of choice in routine lung cancer imaging, and iterative 
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reconstruction techniques have allowed for a significant reduction of radiation dose with 
overall similar image quality (Figure 2).2345 Quantitative analysis of CT data can provide 
accurate anatomical information about NSCLC and the surrounding lung. In principle, 
lung nodule volumetric measurement and comparison across interval CT scans is 
relatively easy and reproducible on the same scanner hardware. However, imagers and 
oncologists should keep in mind that there is variability in these “objective” CT metrics 
that are introduced by individual reviewer RECIST measurements, manual segmentation 
of tumor volume, and technical factors (e.g.  choice of reconstruction kernel, slice-
thickness, and inter-scanner differences)...46-4824 Any combination of these,  factors may 
cause considerable measurement variability of the tumor burden, making the task more 
challenging for radiologists. We next carefully discuss the various technical factors that 
may impact tumor measurement accuracy. 
 
a. CT Reconstruction algorithms and radiation dose 
Previous studies have investigated the influence of the reconstruction kernel  
and radiation dose on lung nodule volume using chest phantoms.49-5225,26 The vast 
majority of those studies demonstrated that various iterative reconstructions (e.g. 
adaptive statistical iterative reconstruction, iDose, and model based iterative 
reconstruction) showed no significant variability in nodule diameter or volume 
measurement when compared to filtered back projection.49-5225,26 In fact, some studies 
reported that iterative reconstructions demonstrated better measurement accuracy at a 
reduced radiation dose. They suggested that reduced noise or increased image quality 
from iterative reconstruction helped reduce measurement errors.25,2649,51,53,54 In a study 
comparing lung cancer screening individuals who underwent low dose CT and ultra-low 
dose CT with iterative reconstruction, there was no significant difference in nodule size 
and volume measurement between the two protocols.2755 In a recent study comparing 
subsolid nodules between model-based iterative reconstruction and filtered back 
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projection, Cohen et al. demonstrated that semi-automatic measurements of diameter, 
volume, and solid components of the subsolid nodules were within the range of 
measurement variability.2856 Thus, lung nodule volumetric measurements acquired from 
scans with different reconstruction techniques can be reliably compared. 
 
b. Slice thickness and reconstruction kernel 
Prior studies have investigated the impact of slice thickness on tumor 
measurement for cancer screening or tumor response evaluation.57-6129,30 Significant 
differences in volume according to CT slice thickness variation were noted for smaller 
lung nodules, where thicker slices introduced greater measurement variability.57,58,6129,30 
The reason for this is related to partial volume effects. Given that a thicker CT slice 
contains larger partial volume artifacts than a thinner image, the margin of the tumor is 
blurred on thicker images. The lack of isotropic voxels for Lung CT influences NSCLC 
nodule segmentation and any extracted radiomics features.3162 In cases of subcentimeter 
nodules, which have very small VOI, partial volume artifacts substantially influences the 
volume measurement.1225  
Similarly, when employing radiomics, recent studies have shown that thin-slice 
images were better than thick-slice images for radiomics features.31,3262,63 In patients 
with lung cancer, He et al. reported that a radiomics signature based on thin slices (1.25 
mm) demonstrated better diagnostic performance than when applied to thick slices (5 
mm).3263 In a chest phantom study, thinner (1.25 mm and 2.5 mm) slice thickness was 
found to be better for radiomics features (e.g. quantifying tumor size, shape, and 
density).3162 To minimize measurement variability thinner slice images are recommend, 
slice thickness should be the same and slices of different thickness should not be mixed 
together for analysis (Figure 3).  
Studies comparing tumor volumes at different reconstruction kernels are scarce 
and have conflicting results. One study reported that, compared to sharp kernels, soft 
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tissue reconstructions demonstrated more repeatable volumetric measurements.3364 
Another study reported that, compared to high frequency bone algorithms, low 
frequency soft algorithms demonstrated larger volumes.43,6534  
 
c. Effects of respiration and intravenous contrast 
Differences in lung inflation should not be underestimated when measuring lung 
nodules. For example, collapse of the alveoli at expiration may bring over and 
underestimation of tumor size, whereas stretching of the tumor parenchyma and blurring 
of the tumor margins could be responsible for an apparent larger tumor size at 
inspiration. Interestingly, results of significant changes in apparent tumor volume during 
the respiratory cycle have been previously reported.1225 Furthermore, motion artefacts 
during respiration can significantly affect the ability to segment lung nodules, rendering 
their outline and volume assessment unreliable. In addition, the presence of a pleural 
effusion or pneumothorax may also have a large influence on the apparent tumor 
volume.66 For radiomics, Oliver et al. suggested that approximately 75% of the current 
dictionary of CT radiomics features are susceptible to respiration.3567  
Another interesting point is the impact of intravenous contrast material on lung 
nodule volume. Due to increased attenuation of the peripheral portion of a nodule at 
post-contrast scans (more vascular and viable region of the tumor nodule), the contrast 
difference between the parenchyma and the nodule increases; thus, volume 
segmentation may include a greater area of the peripheral lung nodule.2243 Results from 
two studies showed that, although the precise increase in nodule volume was small, 
radiologists should be aware of this artifact on the contrast enhanced exams.36,3768,69  
 
B. MRI 
Owing to the ability of MRI to gather multiparametric data from NSCLC, MRI may 
play an increasing role in categorizing the therapeutic response in lung cancer.38,3970,71 
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MRI is more reproducible in the identification of NSCLC and has superior soft tissue 
contrast in comparison to CT.72 MRI lung nodule volumes are smaller than CT lung nodule 
volumes due to the higher resolution of CT and the magnetic susceptibility of air 
surrounding.73,7440 Ideally, for quantitative analysis, MRI images should all have the same 
field of view and acquisition matrix, field strength, and slice thickness. Each one of these 
acquisition parameters which have a strong effect on signal-to-noise ratio.3971 However, 
the many choices for acquisition in Lung MRI complicates comparison between studies of 
the many features extracted from the images.4175 Standardization of Lung MRI protocols 
in the setting of gathering radiomic features from NSCLC will be very helpful. 
a. Magnetic field strengths 
As MR field strength increases, the signal-to-noise (SNR) increases. This increase 
in the SNR can be utilized to for an increase in the number of phase encoded steps for 
better spatial resolution and improved anatomical identification.40,4274,76 The use of 
higher MR field strength improves the ability to contour tumor masses and reduces the 
measurement variability.4074 However, as MR field strength increases, it is accompanied 
by Bo and B1 inhomogeneity, an increased number of image artifacts due to changes in 
tissue magnetic susceptibility and increase in chemical shift,76,7742 B1 inhomogeneity 
results in systematic error for T1 measurement.4378 In oncology practice, tumor necrosis 
from response to anticancer therapies leads to increased water diffusion. This results in 
higher signal intensity on the higher-b-value images, and the apparent diffusion 
coefficient (ADC) value of the corresponding region will typically increase as there is no 
restriction to the diffusion of water with a destruction of the closely packed cell 
membranes. Changes in ADC on DWI have been shown to be effective for monitoring 
therapeutic response in solid tumore.79-8144 Therefore, the field strength should be 
considered to evaluate the therapeutic response with ADC value. 
There are field strength-related changes on the relaxivity of MR contrast media. 
The relaxivity of gadolinium based MR contrast media increases 5% to 10% when 
Formatted: Superscript
Field Code Changed
Field Code Changed
Field Code Changed
Field Code Changed
Formatted: Superscript
Field Code Changed
Formatted: Superscript
changing from 1.5T to 3T.4276 The individual dependencies of relaxivities on field strength 
for the types of MR contrast media were significantly different (Table 1).45,4682,83 
Successful treatment leads to decreased magnitude of enhancement. For detecting 
change of enhancement of tumor, dosing for contrast media would need to be modified 
according to field strength.  
 
b. MRI Acquisition parameters for staging of lung cancer 
In patients with lung cancer, MRIs have been widely used to evaluate invasion of 
mediastinum and organs because of superior soft tissue contrast. With advancement of 
MR techniques, size threshold for nodules have increased, and MR has potential role for 
assessing indeterminate lung nodules.4784 With short echo times, fast spin echo 
sequences have enabled to assess NSCLC, however, T2 blurring affected the 
reproducibility of the evaluation of NSCLC.4885 Ultrashort echo time (UTE) with the 
exceedingly short T2 and T2* relaxation times of the lungs has been used in nodule 
detection and nodule type classification47,4984,86. However, UTE sequences have the 
disadvantages of long scan duration because of inefficient k-space coverage and are 
sensitive to motion artifacts.5087 3D UTE provide isotropic spatial resolution with full 
chest coverage and is less sensitive to motion artifacts.4885 The use of limited field-of-
view excitation, variable readout gradient, and radial oversampling improves image 
quality on 3D UTE.4885 Most 3D UTE sequences have acquired images using radial-based 
trajectories.5087 A recent study by Ohno et al. showed that UTE images with radial 
acquisition was useful in detection and classification of pulmonary nodules larger than 4 
mm, and interobserver agreement for nodule classification was excellent (κ = 0.95).4986 
In addition, UTEs with spiral trajectories over a radial readout are reported to have the 
advantage of high k-space coverage speed while preserving image quality.5087 A study 
reported that there was a 100% detection rate for nodules 5 mm or larger and 76.7% 
for 2-5 mm nodules on 3D UTE with stack-of-spirals trajectory.5087   
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 Short T1 inversion recovery (STIR) turbo spin-echo imaging sequence, which is 
very sensitive to change in T1 and T2, has been known as an important sequence in 
pulmonary MR imaging.8851 The specificity (60.6%) and accuracy (74.5%) of STIR were 
higher than T1 (37.9% and 67.9%) and T2 (48.5% and 67.9%) in distinguishing 
malignant from benign nodules.5189 Therefore, STIR sequence could be used to 
characterize lung nodule, and assess clinical stage of NSCLC. DWI could be useful in 
assessment of lung nodules, the staging, and early detection and prediction of treatment 
response of NSCLC. With high lesion-to-background ratio on high b-value images, DWI is 
useful in the detection of lung nodules. In addition, DWI allows for the characterization 
of lung nodules using a quantitative assessment of diffusion of water molecules by 
calculating the ADC.4784 Thus, ADC is widely used a quantitative imaging biomarker in 
evaluating NSCLC. A study reported that ADC value increased by 25% after one cycle of 
chemotherapy due to tumor necrosis and apoptosis, and this suggest that early response 
of treatment can be predicted by means of ADC change.5290 However, the DWI-based 
evaluation of lung nodule can show the difference in value depending on the quantitative 
evaluation method and b value selection.5290 Due to the impact of b value selection on 
DWI, quantitative parameter values should be changed depend on b value selection. 
Susceptibility artifacts is one of the reasons for the lower ADC differentiation of lung 
nodule. As b value increased, the change of distortion and susceptibility artifacts 
increased, and results in poor SNR.5391. The interobserver coefficient of variation of ADC 
in nodules less than 2 cm was relatively poor.5492. Contrast-enhanced T1 sequence can be 
used to characterize lung nodules according to contrast enhancement patterns as well as 
difference in signal intensity before and after injection of contrast agent.5290 Contrast 
enhancement with gadolinium contrast agent on T1-weighted gradient-recalled echo 
(GRE) or turbo GRE sequences is superior to those on spin-echo and turbo spin-echo 
(TSE) sequences.5593. 
 Quantitative features than can be derived from medical images helps to evaluate 
of lung cancer.614 Entropy was known as the most reproducible MR parameter reflecting 
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tumor heterogeneity.5694 A recent study showed that histogram and texture parameters 
varied after contrast agent injection on DCE MRI, and the 120-150 second after contrast 
agent infection was optimal for analysis of MR texture parameter.5694 The effects of 
acquisition parameter variations on pixel signal intensities are masked because of 
blurring and partial volume effects, thus reducing the effect on the radiomics features. 
Repeatability of MR quantitative parameters is better for global features such as first-
order statistical histogram and model-based fractal features than for local-regional 
texture parameters.3870 
 
c. Compensating for respiratory motion 
There is an artificial increase in the volume of a solitary NSCLC during inspiration 
because of stretching of the tumor and the surrounding peritumoral lung parenchyma 
1225 Moreover, breathing-related motion can decrease the signal intensity on MRI 
particularly in areas of dynamic air trapping. During inspiration, lung volume is larger; 
thus, tissue density and MR signal are lower.5795 Perfusion could be evaluated 
qualitatively and quantitatively, and perfusion MRI is performed during breath hold to 
minimize artifacts from respiration motion because of the fast transit time of contrast 
agent. However, measurement of perfusion depends strongly on the level of inspiration. 
During inspiration, pulmonary vascular resistance is increased, while right atrial filling is 
increased due to the drop in intrapleural pressure. One consequence of this change in 
physiology is that perfusion at during a breath hold MR angiography exam performed at 
full inspiration (total lung capacity) is lower than perfusion performed at  full expiration 
(residual volume). It is difficult to control the degree of inspiration during breath 
hold.5896 Therefore, measurements of perfusion performed with have relatively poor 
reproducibility.5795 Some authors have suggested that measurement of perfusion during 
quiet free breathing can be assessed more reproducibly because free breathing offers 
better patient compliance.5795    
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d. Functional MR analysis 
Angiogenesis is one of the important factors in the evaluation of lung cancer related to 
tumor survival and growth. DCE-MRI provides information of tumor angiogenesis such as 
blood flow, vascular volume, and permeability. Once multiple images can be acquired 
during the first transit or recirculation and washout of contrast medium, quantitative 
evaluation of contrast passage kinetics can be made.97,9859 Pulmonary blood flow (PBF), 
pulmonary blood volume (PBV) and mean transit time (MTT) can be generated by means 
of pixel-by-pixel analysis.6099 In addition, an arterial input function (AIF), rate of change 
in the concentration of contrast medium in the plasma with time, is quantified in the 
larger arteries including main pulmonary.59,6197,100 An accurate AIF is necessary for 
quantitative analysis.61100 AIF allows conversion of signal time curves to concentration 
time curves from assumption of a linear relation between the signal intensity and the 
concentration of contrast agent.97,10159  
Quantitative evaluation of DCE-MRI is based on many pharmacokinetic models, 
and the Toft’s and Kermode model (ToftsToft’s model, Table 2 and figure 4) are the most 
frequently used in DCE –MRI analysis.61100 The ToftsToft’s model was originally 
constructed with ignoring the effect of intravascular tracer62102: 
C(t) = Ktrans e-tkep * Ca(t)                                       [1] 
Where “*” is convolution, and C(t) and Ca(t) are concentration-time curves in the tissues 
in interest and in the plasma of a feeding artery, respectively. The standardized terms 
are presented in Table 2. The parameters of Ktrans and kep are defined as follows102-10462: 
   Ktrans = EFp Kep = EFp /ve                                   [2] 
Where ve is the fractional volume of the extravascular extracellular space (EES), Fp is the 
flow of plasma in the capillary bed, and E is related to Fp and the permeability-surface 
are permeability surface area product of the endothelial wall. The assumption of 
negligible plasma volume is invalid, particularly tumor tissues. To overcome the 
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limitation, the Tofts model has been formulated to allow for an intravascular contribution, 
which is referred as the extended Tofts model.62 
C(t) = vpCa(t) + Ktrans e-tkep * Ca(t)                              
[3] 
vp is the fractional volume of the plasma space.  
Various factors could affect the reliability of results in DCE-MRI. The accuracy and 
precision of pharmacokinetic parameter estimates are strongly influenced by SNR, and 
temporal resolution.61100 Using a theoretical AIF, differences in injection rate and cardiac 
output are ignored, which may differ between subjects and for a single subject over 
time.63105 Measurement of suboptimal AIF results in worse reproducibility than if a 
standardized AIF is used, although the AIF might be not so important for evaluating 
treatment response.64106 In addition, blood supply of lung takes places through both the 
dual pulmonary and bronchial arterial systems.98 Primary lung cancers are supplied by 
dual blood supply and the bronchial circulation plays an important role in lung cancer, 
especially when the size of tumor is larger.65107 The single input perfusion analysis 
according to the maximum slope method calculated the dominant circulation, and 
ignored the secondary circulation, therefore the result of perfusion of lung cancer are 
likely to be underestimated.66108 To overcome underestimation of perfusion, the dual-
input perfusion analysis technique is employed in lung cancer perfusion analysis, and a 
study reported that dual-input perfusion analysis is helpful for predicting the treatment 
effect of multi-arterial infusion chemotherapy.66108 
 
C. PET 
Due to its quantitative ability and ability to target cellular biology the use of PET 
has continuously increased for the assessment of therapeutic response in lung cancer. 
The most commonly used variable is the standardized uptake value (SUV) of 18F-
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deoxyglucose (FDG)-based quantitative PET parameters are used as radiomics features 
and therapeutic response criteria. Many biological and technical factors affect the 
measurement of SUV, which are described below.67109  
a. Normalization method for SUV calculation 
SUV is calculated by activity concentration in tissue adjusted by the administered 
dose of radiopharmaceutical, background SUV of the blood pool and body size. Body size 
usually corresponds to the body weight of the patient (SUVbw). However, other indexes 
such as lean body mass (SUVlbm) or body surface area (SUVbsa) can also be used. The 
choice of how to normalize SUV affects the measurement of SUV and how this value can 
be used in comparing other studies for therapeutic response to specific agent. One 
disadvantage of SUVbw is its known overestimation in obese patients. Both SUVbw and 
SUVbsa are less sensitive to patient weight.68110,111 
b. b. PET/CT scanner models and image acquisition/reconstruction 
protocol 
PET/CT hardware models, image acquisition and reconstruction protocols also 
affect the quantitative measurement of SUV. For the performance of PET/CT scanners, 
the most important factors are the intrinsic resolution and  detector sensitivity. These 
key parameters directly affect in-plane resolution and voxel size  which  determines the 
amount of partial volume artifact and, SUV variability. This is magnified in the lung bases 
where nodules move with respiration further adding to volume averaging artifacts and 
image misregistration with respect to the CT used for attenuation correction. 
In the image acquisition protocol, one of most important factors is uptake time. 
Uptake time is defined as the time interval between the injection of the PET 
radiopharmaceutical and start of PET scanning. This also influences the measurement of 
SUV. In the case of 18F- FDG, the most common uptake time is 60 min. The SUV after 
FDG injection continuously increases as metabolically active cells take up the glucose 
analogue, which is subsequently trapped.69112 Therefore, the use of a fixed uptake time 
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is important for the consistency of SUV measurement. On the other hand total scan 
duration or scan mode (2D vs. 3D) does not have a significant effect on SUV 
accuracy.70113 
In the reconstruction protocols, the attenuation correction method, 
reconstruction method (analytical vs. statistical/iterative methods), and smoothing filter 
are major factors affecting SUV measurement. For example, increased smoothing results 
in decreased noise and increased bias. Increased bias will result in reduced SUV.71114 
c. c. Patient factors 
Even with the same PET/CT protocols and within the same patient repeatability is 
an important issue. SUV can vary due to the biological process such as different blood 
glucose and insulin levels, this leads to a high test-retest variability.72115 It is well known 
that plasma serum blood glucose level is inversely correlated with SUVs.73116 
d. d. Types of quantitative PET parameters 
Most quantitative PET parameters have important problems related to 
measurement variability, precision and repeatability. This includes maximum SUV, 
average SUV, peak SUV, metabolic tumor volume (MTV), and total lesion glycolysis 
(TLG).117 Although maximum SUV is usually not affected by the determination of lesion 
region of interest (ROI) or VOI, in other PET parameters, ROI/VOI has significant 
influence. However, there is a persistent concern that maximum SUV represents a single 
pixel value that may not be representative of the total metabolic profile of the tumor. 
According to previous studies of NSCLC, MTV and TLG were better prognostic measures 
than maximum SUV and mean SUV,118,11974 suggesting that volume-based parameters of 
PET may have a role in providing further prognostic information.74,75120 
e. e. Harmonization of PET parameters 
Based on the literature, the measurement variability of maximum SUV, average 
SUV, and peak SUV expressed as a coefficient of variation is approximately 10%.76121 
Field Code Changed
Field Code Changed
Formatted: Normal, Indent: Left:  0.83", First line: 
0.28",  No bullets or numbering
Formatted: Font: (Default) Verdana, Font color: Text
1
Field Code Changed
Field Code Changed
Formatted: Normal, Indent: Left:  0.83", First line: 
0.28",  No bullets or numbering
Formatted: Font: (Default) Verdana, Font color: Text
1
Formatted: Superscript
Formatted: Superscript
Formatted: Indent: Left:  1.14",  No bullets or
numbering
Field Code Changed
Due to these measurement variabilities the harmonization of PET response criteria has 
been studied. For example, image reconstruction-related variability can be solved using a 
standardized filter such as EQ.PET.77122 To apply this kind of standardized filter for image 
reconstruction, it is necessary to obtain recovery coefficients according to the lesion size 
by National Electrical Manufacturers Association (NEMA) NU-2 phantom.78123 However, 
further efforts are necessary to standardize the quantitative measurement of PET 
parameters.  
f. f. PET Radiotracers for lung cancer 
Representative PET radiotracers for lung cancer and their clinical utilities are 
summarized in Table 3. FDG, a glucose analogue, is the most widely used PET radiotracer 
for lung cancer. It is clinically useful for the single pulmonary nodule evaluation, initial 
staging, detecting recurrence, and therapy response evaluation.79124 18F-Fluorothymidine 
PET is good for evaluating therapy response to radiotherapy or chemotherapy early in 
lung cancer.80125 18F-fluoromisonidazole PET shows the hypoxic portion within the tumor, 
which can be used for radiotherapy planning in lung cancer by boosting radiation dose to 
hypoxic tumor.81126 18F-alfatide, reflecting tumor angiogenesis, has a potential to 
evaluate therapy response in lung cancer, although published studies were very few.82127 
PET tracers targeting tumor epidermal growth factor receptor (EGFR) such as 11C-
PD153035 and 11C-erlotinib may be applicable for therapy response evaluation to EGFR–
tyrosine kinase inhibitors.128,129.83  
 
3) Special considerations on radiomics analysis 
A. Bin number 
Radiomics analysis computes hundreds or sometimes thousands of features from 
the underlying imaging modalities and ROIs. The features are different from semantic 
features and are agnostic computational features whose formulae are defined with 
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various parameters.130 Thus, for a given radiomics feature, if the associated parameter 
changes, the ensuing radiomics feature might change as well. Many radiomics features, 
noted as histogram-based features, are computed from the intensity histogram using the 
underlying imaging data within the ROI. Histograms are affected by binning parameters 
of bin width and range (Figure 5). Range is application dependent, and we typically use 
4096 for CT. Many people also use a number of bins, which is range divided by bin width 
for the binning parameter. Using many bins allows fine differentiation between intensity 
values, but using too many bins leads to very narrow bin width. A narrow bin width leads 
to unreliable histogram estimates, as we may not have enough samples for some bins. 
The Freedman-Diaconis rule can be used to set bin width.84131,132  
In addition, we are computing hundreds and thousands of features from a given 
ROI, which mightcan frequently lead to having too many parameters in an analytical 
model. This could beresults in thought as overfitting the of data when we areand is an 
important limitation when training an artificial intelligence model with limited samples. 
Thus, it is desirable to have as many as possible.As a general rule there should not be 
more features than patients in the training set. Many recent radiomics papers included 
hundreds or sometimes over one thousand samples.133-13585,86 In practice, not all the 
features are included in the resultant radiomics model. There are often feature selection 
procedure (through least absolute shrinkage and selection operator or something 
equivalent), where the number of features is reduced to a few (i.e., typically tens of 
features).85,87133,136 In this case, having 70-80 samples could still be adequate regarding  
to avoid ing overfitting. 
 
B. Texture features 
Texture features are widely recognized radiomics features.133,137,13885 The most 
representative texture features are computed from gray-level co-occurrence matrix 
(GLCM) and intensity size zone matrix (ISZM). These matrices are built out of 2D 
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histograms, which measure the frequency of a pair of observations compared to a 1D 
histogram, where researchers consider the frequency of one observation (e.g., intensity). 
GLCM measures the frequency of intensity pairs in the neighborhood, while ISZM 
measures the frequency of blobs with certain size and intensity. For GLCM, the 2D 
histogram is built using intensity of the given voxel as the first axis and intensity of the 
neighboring voxel as the second axis. The GLCM quantifies how intensity pairs occur in a 
neighbor and hence can reflect textural information. Similar to the 1D histogram case, 
the number of bins is a major parameter in 2D histograms. In general, the samples in a 
given bin for a 2D histogram is less than those in an equivalent 1D histogram as the 
voxels need to fill the bins spanning the 2D histogram compared to filling the 1D 
histogram. In general, the number of samples in a the 2D histogram areis a lot less as 
the voxels need to fill the bins spanning the 2D space compared to the 1D histogram. 
Due to this sparsity in the 2D histogram, researchers typically use 128/256 bins for 
GLCM.88139 Figure 6 shows typical 1D intensity histogram and 2D GLCM and ISZM 
histograms. 
The size of the ROI also affects the 1D/2D histogram measures. If theyour ROI is 
big enough to contain thousands of voxels, then the above approaches are suitable. If 
thea ROI has a very small number of voxels (perhaps arounde.g. 100), then researchers 
need to reduce the number of bins significantly to make sure there are enough voxels 
occupying the bins.  
 
C. Shape features 
Shape features are important parts of radiomics analysis.133,14085 The shape of 
ROI is quantified with various formulae. ROI is composed of voxels that could be 
isotropic or non-isotropic. In many cases, we havechest imaging there is often good in-
plane resolution and  poorvariable out-of-plane resolution (i.e., non-isotropic voxels). 
For non-isotropic voxels, the shape features are more sensitive to shape change 
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occurring in-plane while less sensitive to shape change occurring out-of-plane. For 
isotropic voxels, the shape features are equally sensitive into all directions. The shape of 
the target ROI may change in any direction; thus, isotropic voxels are preferable over 
non-isotropic ones. If the imaging data is non-isotropic, we can interpolate the imaging 
data to make it isotropic. This interpolation makes the data smoother but at least 
reducesalso reduces the shape variability.  In other words, the fine edge detail is lost. 
This is similar to iterative reconstruction methods in CT used to decrease patient dose. 
The dose is decreased, but fine detail can beis lost in these smoother more “plastic” 
appearing images. 
 
D. Filter and Wavelet 
Some researchers have applied an edge enhancement filter such as Laplacian of 
Gaussian (LoG) to the reconstructed image data and only then compute radiomics 
features from the filtered image.89141 The LoG filter has a scale parameter that controls 
the scale at which enhancement occurs (Figure 7). Researchers need to specify the scale 
parameter to suit their intended application. The scale should be set based on image 
quality and the size of ROI. If researchers have poor quality image with large ROIs, large 
scale operations are recommended.  
Some studies also apply wavelet decomposition to imaging data.85133 The 
imaging data are decomposed into many output data, and radiomics features are then 
computed from the decomposed data. There are many wavelet transforms to choose 
from, each with a plethora of parameters. Coiflets are widely used for their simplicity. 
Researchers can decompose one 3D scan into 8 3D decomposed scans in its simplest 
version. Different wavelet transform leads to different decomposed data and thus affects 
the radiomics features. Researchers should fully consider the various parameters of 
wavelets before applying them in their projects.  
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Future considerations 
 
3. Future Suggestions and Conclusion  
As radiomics features show promising benefits for quantification of lung cancer 
biology and response to treatment, many researchers are now paying close attention to 
the clinical usefulness of radiomics in oncologic studies. However, as the number of 
radiomics studies explodes, it should be clearly noted that the extracted radiomics 
features are subject to lack of precision and repeatability. Therefore, in order to 
homogenize evaluation criteria and reporting guidelines for radiomics, Lambin et al. 
proposed the radiomics quality score (RQS) (Table 4).86134 The RQS evaluates the 
necessary steps in radiomics analysis including 16 key components of which each is 
given a number of points corresponding to the importance of the respective 
component.86134 Major check points in the RQS are data selection, medical imaging, 
features extraction, exploratory analysis, and modeling. The highest possible total RQS 
for quantification of the overall methodology and analysis of radiomics practice is 36 
points. Therefore, efforts should be made to consider RQS in future studies and to 
stablish collaborative foundations to control and fully realize the potential of radiomics.   
One last considerationAnother feature that may help in tumor response 
evaluation is delta radiomics.86,90134,142 In contrast to most radiomics studies, which are 
based on features extracted at a single time point (usually at the time of diagnosis), 
delta radiomics evaluates changes in radiomics features between interval studies. Delta-
radiomics features have shown potential in predicting response or survival in patients 
with colorectal cancer liver metastasis, metastatic renal cell, and lung cancer.90-92142-144  
According to a study of 107 NSCLC patients, pretreatment radiomics features were not 
prognostic, while texture-strength measured at the end of treatment significantly 
stratified high- and low-risk patients, thus suggesting the potential of delta-radiomics 
features.90142 Nevertheless, if delta radiomics were to be employed in clinical practice, 
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standardization of technical factors and high reproducibility of the features remain 
prerequisites. 
In conclusion, compared to the current RECIST version 1.1, tumor volumetric 
measurement and radiomics are more quantitative measures and supplement the 
limitations of RECIST in the current era of precision cancer therapy. Nevertheless, 
substantial variability can be introduced in the process of measuring tumor burden due 
to various technical factors. Furthermore, the increasing role of software post- 
processing and radiomics support the need for increased awareness of technical factors 
of image acquisition among radiologists. We await the incorporation of these advanced 
image processing metrics of Radiomics and Artificial Intelligence into the new RECIST 
criteria for tumor response assessment.In the future, the traditional role of radiological 
practice in oncological studies is likely to change, and the concepts and knowledge 
described in this review will support radiologists with a new perspective for tumor 
response evaluations in the cutting edge cancer patient care. 
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Figure Legends 
Figure 1. Various methods of tumor segmentation. A) Part-solid adenocarcinoma with 
internal air-bronchogram at the right upper lobe. B) Automatic segmentation of the solid 
portion. C) Automatic segmentation of the ground glass opacity (GGO) portion. D) Semi-
automatic segmentation with subjective tumor margin editing demonstrates the final 
solid portion (blue) and GGO portion (red). 
 
Figure 2. Graph demonstrates the attenuation profile along a vertical line through the 
tumor. Tumor margins are assumed by the rapid slope of pixel values. The area of 
negative pixel values within the tumor suggests the presence of air-bronchogram.  
 
Figure 3. As part-solid adenocarcinoma, 5 mm slice images (top row) show less solid 
portion compared to 1.25 mm slice images (bottom row). Thicker-slice image contains 
larger partial volume artifacts than a thinner-slice image, thus influencing the true 
details of lung adenocarcinoma.  
 
Figure 4. The extended Tofts model. Assumption of this model is the equilibrium of the 
contrast agent between the plasma and extravascular extracellular space (EES) 
 
Figure 5. Difference in grey-level co-occurrence matrix  (GLCM) according to number of 
bins. The two GLCMs are from the same patient with different numbers of bins. The 
GLCMs are displayed using the same scale. The left figure has more bins thus can have 
fewer counts per bin, while the right figure has fewer bins and thus more counts per bin. 
These differences in counts per bin led to different features values of GLCM. 
 
Figure 6. Histogram samples for radiomics. A) 1D Histogram within ROI. In most cases, 
the analysis using CT images considers a full range of HU values (i.e., 4096 bins). B) 2D 
histogram of grey-level co-occurrence matrix (GLCM). The 2D histogram of GLCM is built 
using intensity of given voxel as the first axis and intensity of the neighboring voxel as 
the second axis. C) 2D histogram of intensity size zone matrix (ISZM). The horizontal 
axis denotes intensity, and the vertical axis denotes size of a given blob. 
 
Figure 7. Original image of lung cancer is enhanced by two different methods of Laplace 
of Gaussian. 
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Abstract 
Multimodality imaging measurements of treatment response are critical for clinical 
practice, oncology trials and the evaluation of new treatment modalities. The current 
standard for determining treatment response in non-small cell lung cancer (NSCLC) is 
based on tumor size using the RECIST criteria. Molecular targeted agents and 
immunotherapies often cause morphological change without reduction of tumor size. 
Therefore, it is difficult to evaluate therapeutic response by conventional methods. 
Radiomics is the study of cancer imaging features that are extracted using machine 
learning and other semantic features.  This method can provide comprehensive 
information on tumor phenotypes and can be used to assess therapeutic response in this 
new age of immunotherapy. Delta radiomics, which evaluates the longitudinal changes in 
radiomics features,  shows potential in gauging treatment response in NSCLC. It is well 
known that quantitative measurement methods may be subject to substantial variability 
due to differences in technical factors and require standardization. In this review, we 
describe measurement variability in the evaluation of non-small cell lung cancer and the 
emerging role of radiomics. 
 
Key words: Molecular Targeted Therapy; Immunotherapy; Medical oncology; Phenotype; 
Lung cancer response; Image; Radiomics 
  
Abbreviations: 
ADC : apparent diffusion coefficient  
AIF : arterial input function 
CT : computed tomography 
DCE : dynamic contrast enhanced  
DWI : diffusion-weighted 
EES : extravascular extracellular space 
EGFR : epidermal growth factor receptor  
FDG : fluoro-deoxyglucose 
GGO : ground-glass opacity 
GLCM : gray-level co-occurrence matrix 
GRE : gradient-recalled echo 
ISZM : intensity size zone matrix 
LoG : Laplacian of Gaussian 
MRI : magnetic resonance imaging 
MTT : mean transit time  
MTV : metabolic tumor volume 
NEMA : National Electrical Manufacturers Association 
NSCLC : non-small cell lung cancer 
PBF : pulmonary blood flow  
PBV :pulmonary blood volume  
PET : positron emission tomography  
RECIST : Response Evaluation Criteria In Solid Tumors 
ROI : region of interest 
RQS : radiomics quality score 
SNR : signal-to-noise ratio 
STIR : Short T1 inversion recovery 
SUV : standardized uptake value  
SUVbw : normalization of standardized uptake value for patient body weight  
SUVbsa : normalization of standardized uptake value for body surface area  
SUVlbm : normalization of standardized uptake value for lean body mass 
TLG : total lesion glycolysis  
TSE : turbo spin-echo 
UTE : ultrashort echo time  
VOI : volume of interest 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Introduction 
Assessment of anti-tumor activity of cancer therapies is generally determined by 
an anatomical measurement of tumor burden. Since its first introduction in 2000 and 
subsequent revision in 2009, Response Evaluation Criteria In Solid Tumors (RECIST) has 
served as the reference standard for measuring tumor burden and confirming tumor 
response.1 According to RECIST criteria, measurement is the maximal axial (in-plane) 
unidimensional measurement of a tumor’s diameter. However, this conventional tumor 
size analysis is imperfect due to inter and intra reader measurement variability, 
heterogeneous tumor morphology, and different technical parameters at the time of 
scanning.2 All of these factors contribute to measurement variability, which can lead to 
an erroneous determination of treatment response/progression and  thereby misinform 
treatment decisons.2,3  
During the past decade, due to an improved understanding of cancer biology, a 
vast collection of targeted molecular therapies have been developed. This has led to a 
paradigm shift in the local and systemic treatment of non-small cell lung cancer (NSCLC). 
While conventional chemotherapy is focused on destroying rapidly dividing tumor cells, 
molecular targeted therapy aims at transmembraneous receptors and intracellular 
molecules that are responsible for the survival and proliferation of tumor cells. Molecular 
targeted therapy has been shown to be effective in tumors with specific genomic driver 
mutations. This has opened a new era of tumor response evaluation where the 
limitations of RECIST-based approaches are increasingly being found.4 Cancer 
immunotherapy with immune-checkpoint blockade helps to activate the cancer pateints 
own  immune system to kill the cancer cells.5 Cancer immunotherapy is associated with 
unconventional response patterns that are not accurately characterized by the RECIST 
criteria.4,5 In addition, morphological changes such as tumor necrosis and cavitation 
without concurrent tumor size reduction are frequently observed in the setting of anti-
angiogenic therapy.2,4  
Radiomics is the process of extracting large amounts of advanced quantitative 
information embedded within radiological images. This approach to image analysis aids  
the field of oncology by providing a more quantitative approach for tumor response 
assessment.6 Although state-of-the-art methods have been shown to work well for 
measuring tumor volume, a great deal of variability exists, and radiologists should be 
familiar with the technical variations, benefits, and drawbacks of radiomics regarding 
measurement variability. Furthermore, although computed tomography (CT) continues to 
play an important role, additional imaging modalities such as positron emission 
tomography (PET), magnetic resonance imaging (MRI) dynamic contrast enhanced (DCE) 
perfusion images and MRI diffusion-weighted (DWI) MRI allow for  multiparametric 
assessment of tumor biology (e.g. glucose metabolism, tumor perfusion, and tumor 
hypoxia) of tumor biology.6 Thus, by combining detailed functional and metabolic 
information, these protocols provide a more comprehensive depiction of the tumor 
microenvironment and may allow for an earlier determination of tumor response. The 
purpose of the review is to focus on the technical issues regarding NSCLC tumor 
measurement variability and how radiomics is emerging for the early assessment of 
tumor response. 
 
2. Technical aspects of measurement 
1) Measuring tumor volume  
A. Segmentation 
Precise NSCLC tumor measurement between interval studies is the current basis 
for tumor response assessment. Currently the long axis diameter, a unidimensional 
measurement, remains the standard RECIST criteria for assessment of whether a tumor 
is growing or shrinking, discordant tumor response between primary reviewers and 
secondary reviewers has been reported.3 In a previous study, using RECIST for NSCLC, 
there was a significant difference between readers for unidimensional measurements of 
tumor size. The misclassification rates for progressive disease were 30% and 10% for 
interobserver and intraobserver measurements, respectively.3 The primary reason for 
this variability is related to inter-reader differences in the manual measurements of the 
primary tumor. 3,7 For instance, in the case of a single unidimensional largest diameter 
measurement for RECIST, each reviewer may measure the tumor at different image 
slices. As a solution to this problem, most radiologists now agree that measuring the 
entire tumor volume is more accurate than a single unidimensional RECIST 
measurement.8,9 Many recent publications have shown that volumetric measurements 
demonstrate better reproducibility and repeatability. According to a recent review article, 
although limit of agreement for both manual diameter measurements and semi-
automated volume measurements lies in the same range in terms of absolute 
percentages, the percentage of lung nodules in which an actual inter-reader difference 
found was with 11% far lower for semi-automated nodule volume measurements 
compared to manual diameter measurements, where inter-reader variability occurs 
commonly. 10 Second, volumetric measurement is more sensitive in detecting even small 
changes than is unidimensional measurement.11 For example, in a 10 mm spherical 
nodule, a 1 mm increase of unidimensional diameter corresponds to a 10% increase in 
cross-sectional diameter and a 33% increase in volume.12 Finally, as lung CT post-
processing computer software is becoming widespread, tumor volumetric measurements 
are gaining in popularity. This has now become the standard for oncological trials are 
beginning as their clinical response endpoint11. We will now discuss the factors affecting 
the variability of tumor volume measurement.11 
Segmentation is the process by which humans (manual segmentation) and 
machines delineate tumor boundaries from the surrounding lung. Generally, the whole 
tumor is selected as the volume of interest (VOI), which is usually feasible, but in certain 
cases may be hampered due to indistinct tumor margins.13 For example, when lung 
cancer is surrounded by a pathological abnormality such as post-obstructive pneumonia 
or radiation-induced lung injury, the tumor boundary is frequently obscured. Tissue 
reorganization and post radiation therapy, scar formation disrupts accurate tumor 
segmentation, leading to variability in tumor measurement. 
Among various methods of segmentation, automatic and semi-automatic 
methods using volumetric software have been shown to be more reproducible than 
manual segmentation.13 Although the current “gold standard” is considered to be manual 
segmentation drawn by experts, this method has major drawbacks: (1) it is a time-
consuming, (2) labor-intensive task and (3) has inter and intra-reader variability. In a 
study comparing manual and semi-automatic segmentation, the radiomics features 
derived from the latter demonstrated significantly higher reproducibility (p=0.0009; 
intra-class correlation coefficient values of 0.85 and 0.77 for semi-automatic 
segmentation and manual segmentation, respectively) and were more robust compared 
to those derived from manual contouring.14 When comparing repeatability (intra-
algorithm comparisons) and reproducibility (inter-algorithm comparisons) of 
segmentation algorithms, repeatability was significantly higher than the reproducibility 
(p<0.007; average Dice score of 0.95 and 0.81 for repeatability and reproducibility, 
respectively), recommending that the same software be used at all time points in 
longitudinal studies.15 However, in cases of part-solid adenocarcinomas, which have a 
ground-glass opacity (GGO) component, fully automatic segmentation is also be 
problematic due to the reduced contrast between the GGO component and surrounding 
lung parenchyma.16 Thus, as of today, for part-solid adenocarcinomas, semi-automatic 
segmentation with tumor margin editing based on subjective decision by an experienced 
expert remains the optimal choice for accurate volumetric assessments of NSCLC (Figure 
1).17 Likewise, advanced NSCLC lung cancer patients with large tumors having irregular 
margins, heterogeneous intra-tumoral texture and surrounding atelectasis or effusions often    
require semi-automated approach with expert radiologist manual editing of the 
segmentation.9 In the setting of molecular targeted therapy for NSCLC, tumor volumes 
obtained by a semi-automated approach have been shown to be a prognostic marker for 
improved survival, solidifying its value in this era of precision medicine.8,18  
In terms of rapid and accurate tumor segmentation, fully automatic 
segmentation methods based on deep learning may be the solution. Several 
investigators have trained convolutional neural networks and demonstrated that deep 
learning is capable of performing accurate localization and segmentation of tumors in 
multiple organs.19,20 Although most of these articles were based on MRI scans, such as 
brain, prostate, and rectum, deep learning technologies have shown potential to improve 
accuracy and robustness of tumor segmentation. 
Another point that needs to be highlighted is the usage of different vendor 
volumetric software platforms. Studies comparing multiple volumetric software packages 
found considerable variation in nodule volume. This shows that that the results of 
software packages should not be used interchangeably.21,22 Next we discuss the impact 
of technical factors at the time of CT acquisition and CT reconstruction such as radiation 
dose, iterative reconstruction, inspiration, and slice thickness on the variability in 
volumetric measurement. 
 
2) Technical issues according to particular imaging modality 
A. CT  
Chest CT is the modality of choice in routine lung cancer imaging, and iterative 
reconstruction techniques have allowed for a significant reduction of radiation dose with 
overall similar image quality (Figure 2).23 Quantitative analysis of CT data can provide 
accurate anatomical information about NSCLC and the surrounding lung. In principle, 
lung nodule volumetric measurement and comparison across interval CT scans is 
relatively easy and reproducible on the same scanner hardware. However, imagers and 
oncologists should keep in mind that there is variability in these “objective” CT metrics 
that are introduced by individual reviewer RECIST measurements, manual segmentation 
of tumor volume, and technical factors (e.g.  choice of reconstruction kernel, slice-
thickness, and inter-scanner differences).24 Any combination of these, factors may cause 
considerable measurement variability of the tumor burden, making the task more 
challenging for radiologists. We next carefully discuss the various technical factors that 
may impact tumor measurement accuracy. 
 
a. CT Reconstruction algorithms and radiation dose 
Previous studies have investigated the influence of the reconstruction kernel  
and radiation dose on lung nodule volume using chest phantoms.25,26 The vast majority 
of those studies demonstrated that various iterative reconstructions (e.g. adaptive 
statistical iterative reconstruction, iDose, and model based iterative reconstruction) 
showed no significant variability in nodule diameter or volume measurement when 
compared to filtered back projection.25,26 In fact, some studies reported that iterative 
reconstructions demonstrated better measurement accuracy at a reduced radiation dose. 
They suggested that reduced noise or increased image quality from iterative 
reconstruction helped reduce measurement errors.25,26 In a study comparing lung cancer 
screening individuals who underwent low dose CT and ultra-low dose CT with iterative 
reconstruction, there was no significant difference in nodule size and volume 
measurement between the two protocols.27 In a recent study comparing subsolid nodules 
between model-based iterative reconstruction and filtered back projection, Cohen et al. 
demonstrated that semi-automatic measurements of diameter, volume, and solid 
components of the subsolid nodules were within the range of measurement variability.28 
Thus, lung nodule volumetric measurements acquired from scans with different 
reconstruction techniques can be reliably compared. 
 
b. Slice thickness and reconstruction kernel 
Prior studies have investigated the impact of slice thickness on tumor 
measurement for cancer screening or tumor response evaluation.29,30 Significant 
differences in volume according to CT slice thickness variation were noted for smaller 
lung nodules, where thicker slices introduced greater measurement variability.29,30 The 
reason for this is related to partial volume effects. Given that a thicker CT slice contains 
larger partial volume artifacts than a thinner image, the margin of the tumor is blurred 
on thicker images. The lack of isotropic voxels for Lung CT influences NSCLC nodule 
segmentation and any extracted radiomics features.31 In cases of subcentimeter nodules, 
which have very small VOI, partial volume artifacts substantially influences the volume 
measurement.12  
Similarly, when employing radiomics, recent studies have shown that thin-slice 
images were better than thick-slice images for radiomics features.31,32 In patients with 
lung cancer, He et al. reported that a radiomics signature based on thin slices (1.25 mm) 
demonstrated better diagnostic performance than when applied to thick slices (5 mm).32 
In a chest phantom study, thinner (1.25 mm and 2.5 mm) slice thickness was found to 
be better for radiomics features (e.g. quantifying tumor size, shape, and density).31 To 
minimize measurement variability thinner slice images are recommend, slice thickness 
should be the same and slices of different thickness should not be mixed together for 
analysis (Figure 3).  
Studies comparing tumor volumes at different reconstruction kernels are scarce 
and have conflicting results. One study reported that, compared to sharp kernels, soft 
tissue reconstructions demonstrated more repeatable volumetric measurements.33 
Another study reported that, compared to high frequency bone algorithms, low 
frequency soft algorithms demonstrated larger volumes.34  
 
c. Effects of respiration and intravenous contrast 
Differences in lung inflation should not be underestimated when measuring lung 
nodules. For example, collapse of the alveoli at expiration may bring over and 
underestimation of tumor size, whereas stretching of the tumor parenchyma and blurring 
of the tumor margins could be responsible for an apparent larger tumor size at 
inspiration. Interestingly, results of significant changes in apparent tumor volume during 
the respiratory cycle have been previously reported.12 Furthermore, motion artefacts 
during respiration can significantly affect the ability to segment lung nodules, rendering 
their outline and volume assessment unreliable. In addition, the presence of a pleural 
effusion or pneumothorax may also have a large influence on the apparent tumor volume. 
For radiomics, Oliver et al. suggested that approximately 75% of the current dictionary 
of CT radiomics features are susceptible to respiration.35  
Another interesting point is the impact of intravenous contrast material on lung 
nodule volume. Due to increased attenuation of the peripheral portion of a nodule at 
post-contrast scans (more vascular and viable region of the tumor nodule), the contrast 
difference between the parenchyma and the nodule increases; thus, volume 
segmentation may include a greater area of the peripheral lung nodule.22 Results from 
two studies showed that, although the precise increase in nodule volume was small, 
radiologists should be aware of this artifact on the contrast enhanced exams.36,37  
 
B. MRI 
Owing to the ability of MRI to gather multiparametric data from NSCLC, MRI may 
play an increasing role in categorizing the therapeutic response in lung cancer.38,39 MRI is 
more reproducible in the identification of NSCLC and has superior soft tissue contrast in 
comparison to CT. MRI lung nodule volumes are smaller than CT lung nodule volumes 
due to the higher resolution of CT and the magnetic susceptibility of air surrounding.40 
Ideally, for quantitative analysis, MRI images should all have the same field of view and 
acquisition matrix, field strength, and slice thickness. Each one of these acquisition 
parameters which have a strong effect on signal-to-noise ratio.39 However, the many 
choices for acquisition in Lung MRI complicates comparison between studies of the many 
features extracted from the images.41 Standardization of Lung MRI protocols in the 
setting of gathering radiomic features from NSCLC will be very helpful. 
a. Magnetic field strengths 
As MR field strength increases, the signal-to-noise (SNR) increases. This increase 
in the SNR can be utilized to for an increase in the number of phase encoded steps for 
better spatial resolution and improved anatomical identification.40,42 The use of higher 
MR field strength improves the ability to contour tumor masses and reduces the 
measurement variability.40 However, as MR field strength increases, it is accompanied by 
Bo and B1 inhomogeneity, an increased number of image artifacts due to changes in 
tissue magnetic susceptibility and increase in chemical shift,42 B1 inhomogeneity results 
in systematic error for T1 measurement.43 In oncology practice, tumor necrosis from 
response to anticancer therapies leads to increased water diffusion. This results in higher 
signal intensity on the higher-b-value images, and the apparent diffusion coefficient 
(ADC) value of the corresponding region will typically increase as there is no restriction 
to the diffusion of water with a destruction of the closely packed cell membranes. 
Changes in ADC on DWI have been shown to be effective for monitoring therapeutic 
response in solid tumore.44 Therefore, the field strength should be considered to 
evaluate the therapeutic response with ADC value. 
There are field strength-related changes on the relaxivity of MR contrast media. 
The relaxivity of gadolinium based MR contrast media increases 5% to 10% when 
changing from 1.5T to 3T.42 The individual dependencies of relaxivities on field strength 
for the types of MR contrast media were significantly different (Table 1).45,46 Successful 
treatment leads to decreased magnitude of enhancement. For detecting change of 
enhancement of tumor, dosing for contrast media would need to be modified according 
to field strength.  
 
b. MRI Acquisition parameters for staging of lung cancer 
In patients with lung cancer, MRIs have been widely used to evaluate invasion of 
mediastinum and organs because of superior soft tissue contrast. With advancement of 
MR techniques, size threshold for nodules have increased, and MR has potential role for 
assessing indeterminate lung nodules.47 With short echo times, fast spin echo sequences 
have enabled to assess NSCLC, however, T2 blurring affected the reproducibility of the 
evaluation of NSCLC.48 Ultrashort echo time (UTE) with the exceedingly short T2 and T2* 
relaxation times of the lungs has been used in nodule detection and nodule type 
classification47,49. However, UTE sequences have the disadvantages of long scan duration 
because of inefficient k-space coverage and are sensitive to motion artifacts.50 3D UTE 
provide isotropic spatial resolution with full chest coverage and is less sensitive to motion 
artifacts.48 The use of limited field-of-view excitation, variable readout gradient, and 
radial oversampling improves image quality on 3D UTE.48 Most 3D UTE sequences have 
acquired images using radial-based trajectories.50 A recent study by Ohno et al. showed 
that UTE images with radial acquisition was useful in detection and classification of 
pulmonary nodules larger than 4 mm, and interobserver agreement for nodule 
classification was excellent (κ = 0.95).49 In addition, UTEs with spiral trajectories over a 
radial readout are reported to have the advantage of high k-space coverage speed while 
preserving image quality.50 A study reported that there was a 100% detection rate for 
nodules 5 mm or larger and 76.7% for 2-5 mm nodules on 3D UTE with stack-of-spirals 
trajectory.50   
 Short T1 inversion recovery (STIR) turbo spin-echo imaging sequence, which is 
very sensitive to change in T1 and T2, has been known as an important sequence in 
pulmonary MR imaging.51 The specificity (60.6%) and accuracy (74.5%) of STIR were 
higher than T1 (37.9% and 67.9%) and T2 (48.5% and 67.9%) in distinguishing 
malignant from benign nodules.51 Therefore, STIR sequence could be used to 
characterize lung nodule, and assess clinical stage of NSCLC. DWI could be useful in 
assessment of lung nodules, the staging, and early detection and prediction of treatment 
response of NSCLC. With high lesion-to-background ratio on high b-value images, DWI is 
useful in the detection of lung nodules. In addition, DWI allows for the characterization 
of lung nodules using a quantitative assessment of diffusion of water molecules by 
calculating the ADC.47 Thus, ADC is widely used a quantitative imaging biomarker in 
evaluating NSCLC. A study reported that ADC value increased by 25% after one cycle of 
chemotherapy due to tumor necrosis and apoptosis, and this suggest that early response 
of treatment can be predicted by means of ADC change.52 However, the DWI-based 
evaluation of lung nodule can show the difference in value depending on the quantitative 
evaluation method and b value selection.52 Due to the impact of b value selection on DWI, 
quantitative parameter values should be changed depend on b value selection. 
Susceptibility artifacts is one of the reasons for the lower ADC differentiation of lung 
nodule. As b value increased, the change of distortion and susceptibility artifacts 
increased, and results in poor SNR.53. The interobserver coefficient of variation of ADC in 
nodules less than 2 cm was relatively poor.54. Contrast-enhanced T1 sequence can be 
used to characterize lung nodules according to contrast enhancement patterns as well as 
difference in signal intensity before and after injection of contrast agent.52 Contrast 
enhancement with gadolinium contrast agent on T1-weighted gradient-recalled echo 
(GRE) or turbo GRE sequences is superior to those on spin-echo and turbo spin-echo 
(TSE) sequences.55. 
 Quantitative features than can be derived from medical images helps to evaluate 
of lung cancer.6 Entropy was known as the most reproducible MR parameter reflecting 
tumor heterogeneity.56 A recent study showed that histogram and texture parameters 
varied after contrast agent injection on DCE MRI, and the 120-150 second after contrast 
agent infection was optimal for analysis of MR texture parameter.56 The effects of 
acquisition parameter variations on pixel signal intensities are masked because of 
blurring and partial volume effects, thus reducing the effect on the radiomics features. 
Repeatability of MR quantitative parameters is better for global features such as first-
order statistical histogram and model-based fractal features than for local-regional 
texture parameters.38 
 c. Compensating for respiratory motion 
There is an artificial increase in the volume of a solitary NSCLC during inspiration 
because of stretching of the tumor and the surrounding peritumoral lung parenchyma 12 
Moreover, breathing-related motion can decrease the signal intensity on MRI particularly 
in areas of dynamic air trapping. During inspiration, lung volume is larger; thus, tissue 
density and MR signal are lower.57 Perfusion could be evaluated qualitatively and 
quantitatively, and perfusion MRI is performed during breath hold to minimize artifacts 
from respiration motion because of the fast transit time of contrast agent. However, 
measurement of perfusion depends strongly on the level of inspiration. During inspiration, 
pulmonary vascular resistance is increased, while right atrial filling is increased due to 
the drop in intrapleural pressure. One consequence of this change in physiology is that 
perfusion at during a breath hold MR angiography exam performed at full inspiration 
(total lung capacity) is lower than perfusion performed at  full expiration (residual 
volume). It is difficult to control the degree of inspiration during breath hold.58 Therefore, 
measurements of perfusion performed with have relatively poor reproducibility.57 Some 
authors have suggested that measurement of perfusion during quiet free breathing can 
be assessed more reproducibly because free breathing offers better patient compliance.57    
d. Functional MR analysis 
Angiogenesis is one of the important factors in the evaluation of lung cancer related to 
tumor survival and growth. DCE-MRI provides information of tumor angiogenesis such as 
blood flow, vascular volume, and permeability. Once multiple images can be acquired 
during the first transit or recirculation and washout of contrast medium, quantitative 
evaluation of contrast passage kinetics can be made.59 Pulmonary blood flow (PBF), 
pulmonary blood volume (PBV) and mean transit time (MTT) can be generated by means 
of pixel-by-pixel analysis.60 In addition, an arterial input function (AIF), rate of change in 
the concentration of contrast medium in the plasma with time, is quantified in the larger 
arteries including main pulmonary.59,61 An accurate AIF is necessary for quantitative 
analysis.61 AIF allows conversion of signal time curves to concentration time curves from 
assumption of a linear relation between the signal intensity and the concentration of 
contrast agent.59  
Quantitative evaluation of DCE-MRI is based on many pharmacokinetic models, 
and the Toft’s and Kermode model (Toft’s model, Table 2 and figure 4) are the most 
frequently used in DCE –MRI analysis.61 The Toft’s model was originally constructed with 
ignoring the effect of intravascular tracer62: 
C(t) = Ktrans e-tkep * Ca(t)                                       [1] 
Where “*” is convolution, and C(t) and Ca(t) are concentration-time curves in the tissues 
in interest and in the plasma of a feeding artery, respectively. The standardized terms 
are presented in Table 2. The parameters of Ktrans and kep are defined as follows62: 
   Ktrans = EFp Kep = EFp /ve                                   [2] 
Where ve is the fractional volume of the extravascular extracellular space (EES), Fp is the 
flow of plasma in the capillary bed, and E is related to Fp and the permeability-surface 
are permeability surface area product of the endothelial wall. The assumption of 
negligible plasma volume is invalid, particularly tumor tissues. To overcome the 
limitation, the Tofts model has been formulated to allow for an intravascular contribution, 
which is referred as the extended Tofts model.62 
C(t) = vpCa(t) + Ktrans e-tkep * Ca(t)                              
[3] 
vp is the fractional volume of the plasma space.  
Various factors could affect the reliability of results in DCE-MRI. The accuracy and 
precision of pharmacokinetic parameter estimates are strongly influenced by SNR, and 
temporal resolution.61 Using a theoretical AIF, differences in injection rate and cardiac 
output are ignored, which may differ between subjects and for a single subject over 
time.63 Measurement of suboptimal AIF results in worse reproducibility than if a 
standardized AIF is used, although the AIF might be not so important for evaluating 
treatment response.64 In addition, blood supply of lung takes places through both the 
dual pulmonary and bronchial arterial systems. Primary lung cancers are supplied by 
dual blood supply and the bronchial circulation plays an important role in lung cancer, 
especially when the size of tumor is larger.65 The single input perfusion analysis 
according to the maximum slope method calculated the dominant circulation, and 
ignored the secondary circulation, therefore the result of perfusion of lung cancer are 
likely to be underestimated.66 To overcome underestimation of perfusion, the dual-input 
perfusion analysis technique is employed in lung cancer perfusion analysis, and a study 
reported that dual-input perfusion analysis is helpful for predicting the treatment effect 
of multi-arterial infusion chemotherapy.66 
 
C. PET 
Due to its quantitative ability and ability to target cellular biology the use of PET 
has continuously increased for the assessment of therapeutic response in lung cancer. 
The most commonly used variable is the standardized uptake value (SUV) of 18F-
deoxyglucose (FDG)-based quantitative PET parameters are used as radiomics features 
and therapeutic response criteria. Many biological and technical factors affect the 
measurement of SUV, which are described below.67  
a. Normalization method for SUV calculation 
SUV is calculated by activity concentration in tissue adjusted by the administered 
dose of radiopharmaceutical, background SUV of the blood pool and body size. Body size 
usually corresponds to the body weight of the patient (SUVbw). However, other indexes 
such as lean body mass (SUVlbm) or body surface area (SUVbsa) can also be used. The 
choice of how to normalize SUV affects the measurement of SUV and how this value can 
be used in comparing other studies for therapeutic response to specific agent. One 
disadvantage of SUVbw is its known overestimation in obese patients. Both SUVbw and 
SUVbsa are less sensitive to patient weight.68 
b. PET/CT scanner models and image acquisition/reconstruction protocol 
PET/CT hardware models, image acquisition and reconstruction protocols also 
affect the quantitative measurement of SUV. For the performance of PET/CT scanners, 
the most important factors are the intrinsic resolution and detector sensitivity. These key 
parameters directly affect in-plane resolution and voxel size which determines the 
amount of partial volume artifact and, SUV variability. This is magnified in the lung bases 
where nodules move with respiration further adding to volume averaging artifacts and 
image misregistration with respect to the CT used for attenuation correction. 
In the image acquisition protocol, one of most important factors is uptake time. 
Uptake time is defined as the time interval between the injection of the PET 
radiopharmaceutical and start of PET scanning. This also influences the measurement of 
SUV. In the case of 18F- FDG, the most common uptake time is 60 min. The SUV after 
FDG injection continuously increases as metabolically active cells take up the glucose 
analogue, which is subsequently trapped.69 Therefore, the use of a fixed uptake time is 
important for the consistency of SUV measurement. On the other hand total scan 
duration or scan mode (2D vs. 3D) does not have a significant effect on SUV accuracy.70 
In the reconstruction protocols, the attenuation correction method, 
reconstruction method (analytical vs. statistical/iterative methods), and smoothing filter 
are major factors affecting SUV measurement. For example, increased smoothing results 
in decreased noise and increased bias. Increased bias will result in reduced SUV.71 
c. Patient factors 
Even with the same PET/CT protocols and within the same patient repeatability is 
an important issue. SUV can vary due to the biological process such as different blood 
glucose and insulin levels, this leads to a high test-retest variability.72 It is well known 
that plasma serum blood glucose level is inversely correlated with SUVs.73 
d. Types of quantitative PET parameters 
Most quantitative PET parameters have important problems related to 
measurement variability, precision and repeatability. This includes maximum SUV, 
average SUV, peak SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG). 
Although maximum SUV is usually not affected by the determination of lesion region of 
interest (ROI) or VOI, in other PET parameters, ROI/VOI has significant influence. 
However, there is a persistent concern that maximum SUV represents a single pixel 
value that may not be representative of the total metabolic profile of the tumor. 
According to previous studies of NSCLC, MTV and TLG were better prognostic measures 
than maximum SUV and mean SUV,74 suggesting that volume-based parameters of PET 
may have a role in providing further prognostic information.74,75 
e. Harmonization of PET parameters 
Based on the literature, the measurement variability of maximum SUV, average 
SUV, and peak SUV expressed as a coefficient of variation is approximately 10%.76 Due 
to these measurement variabilities the harmonization of PET response criteria has been 
studied. For example, image reconstruction-related variability can be solved using a 
standardized filter such as EQ.PET.77 To apply this kind of standardized filter for image 
reconstruction, it is necessary to obtain recovery coefficients according to the lesion size 
by National Electrical Manufacturers Association (NEMA) NU-2 phantom.78 However, 
further efforts are necessary to standardize the quantitative measurement of PET 
parameters.  
f. PET Radiotracers for lung cancer 
Representative PET radiotracers for lung cancer and their clinical utilities are 
summarized in Table 3. FDG, a glucose analogue, is the most widely used PET radiotracer 
for lung cancer. It is clinically useful for the single pulmonary nodule evaluation, initial 
staging, detecting recurrence, and therapy response evaluation.79 18F-Fluorothymidine 
PET is good for evaluating therapy response to radiotherapy or chemotherapy early in 
lung cancer.80 18F-fluoromisonidazole PET shows the hypoxic portion within the tumor, 
which can be used for radiotherapy planning in lung cancer by boosting radiation dose to 
hypoxic tumor.81 18F-alfatide, reflecting tumor angiogenesis, has a potential to evaluate 
therapy response in lung cancer, although published studies were very few.82 PET tracers 
targeting tumor epidermal growth factor receptor (EGFR) such as 11C-PD153035 and 11C-
erlotinib may be applicable for therapy response evaluation to EGFR–tyrosine kinase 
inhibitors.83  
 
3) Special considerations on radiomics analysis 
A. Bin number 
Radiomics analysis computes hundreds or sometimes thousands of features from 
the underlying imaging modalities and ROIs. The features are different from semantic 
features and are agnostic computational features whose formulae are defined with 
various parameters. Thus, for a given radiomics feature, if the associated parameter 
changes, the ensuing radiomics feature might change as well. Many radiomics features, 
noted as histogram-based features, are computed from the intensity histogram using the 
underlying imaging data within the ROI. Histograms are affected by binning parameters 
of bin width and range (Figure 5). Range is application dependent, and we typically use 
4096 for CT. Many people also use a number of bins, which is range divided by bin width 
for the binning parameter. Using many bins allows fine differentiation between intensity 
values, but using too many bins leads to very narrow bin width. A narrow bin width leads 
to unreliable histogram estimates, as we may not have enough samples for some bins. 
The Freedman-Diaconis rule can be used to set bin width.84  
In addition, computing hundreds and thousands of features from a given ROI, 
can frequently lead to having too many parameters in an analytical model. This results in 
overfitting the of data and is an important limitation when training an artificial 
intelligence model with limited samples. As a general rule there should not be more 
features than patients in the training set. Many recent radiomics papers included 
hundreds or sometimes over one thousand samples.85,86 In practice, not all the features 
are included in the resultant radiomics model. There are often feature selection 
procedure (through least absolute shrinkage and selection operator or something 
equivalent), where the number of features is reduced to a few (i.e., typically tens of 
features).85,87 In this case, having 70-80 samples could still be adequate  to avoid 
overfitting. 
 
B. Texture features 
Texture features are widely recognized radiomics features.85 The most 
representative texture features are computed from gray-level co-occurrence matrix 
(GLCM) and intensity size zone matrix (ISZM). These matrices are built out of 2D 
histograms, which measure the frequency of a pair of observations compared to a 1D 
histogram, where researchers consider the frequency of one observation (e.g., intensity). 
GLCM measures the frequency of intensity pairs in the neighborhood, while ISZM 
measures the frequency of blobs with certain size and intensity. For GLCM, the 2D 
histogram is built using intensity of the given voxel as the first axis and intensity of the 
neighboring voxel as the second axis. The GLCM quantifies how intensity pairs occur in a 
neighbor and hence can reflect textural information. Similar to the 1D histogram case, 
the number of bins is a major parameter in 2D histograms. In general, the samples in a 
given bin for a 2D histogram is less than those in an equivalent 1D histogram as the 
voxels need to fill the bins spanning the 2D histogram compared to filling the 1D 
histogram. Due to this sparsity in the 2D histogram, researchers typically use 128/256 
bins for GLCM.88 Figure 6 shows typical 1D intensity histogram and 2D GLCM and ISZM 
histograms. 
The size of the ROI also affects the 1D/2D histogram measures. If the ROI is big 
enough to contain thousands of voxels, then the above approaches are suitable. If the 
ROI has a very small number of voxels (e.g. 100), then researchers need to reduce the 
number of bins significantly to make sure there are enough voxels occupying the bins.  
 
C. Shape features 
Shape features are important parts of radiomics analysis.85 The shape of ROI is 
quantified with various formulae. ROI is composed of voxels that could be isotropic or 
non-isotropic. In chest imaging there is often good in-plane resolution and variable out-
of-plane resolution (i.e., non-isotropic voxels). For non-isotropic voxels, the shape 
features are more sensitive to shape change occurring in-plane while less sensitive to 
shape change occurring out-of-plane. For isotropic voxels, the shape features are equally 
sensitive in all directions. The shape of the target ROI may change in any direction; thus, 
isotropic voxels are preferable over non-isotropic ones. If the imaging data is non-
isotropic, we can interpolate the imaging data to make it isotropic. This interpolation 
makes the data smoother but also reduces the shape variability.  In other words, the 
fine edge detail is lost. This is similar to iterative reconstruction methods in CT used to 
decrease patient dose. The dose is decreased, but fine detail is lost in these smoother 
more “plastic” appearing images. 
 
D. Filter and Wavelet 
Some researchers have applied an edge enhancement filter such as Laplacian of 
Gaussian (LoG) to the reconstructed image data and only then compute radiomics 
features from the filtered image.89 The LoG filter has a scale parameter that controls the 
scale at which enhancement occurs (Figure 7). Researchers need to specify the scale 
parameter to suit their intended application. The scale should be set based on image 
quality and the size of ROI. If researchers have poor quality image with large ROIs, large 
scale operations are recommended.  
Some studies also apply wavelet decomposition to imaging data.85 The imaging 
data are decomposed into many output data, and radiomics features are then computed 
from the decomposed data. There are many wavelet transforms to choose from, each 
with a plethora of parameters. Coiflets are widely used for their simplicity. Researchers 
can decompose one 3D scan into 8 3D decomposed scans in its simplest version. 
Different wavelet transform leads to different decomposed data and thus affects the 
radiomics features. Researchers should fully consider the various parameters of wavelets 
before applying them in their projects.  
Future considerations 
As radiomics features show promising benefits for quantification of lung cancer 
biology and response to treatment, many researchers are now paying close attention to 
the clinical usefulness of radiomics in oncologic studies. However, as the number of 
radiomics studies explodes, it should be clearly noted that the extracted radiomics 
features are subject to lack of precision and repeatability. Therefore, in order to 
homogenize evaluation criteria and reporting guidelines for radiomics, Lambin et al. 
proposed the radiomics quality score (RQS) (Table 4).86 The RQS evaluates the 
necessary steps in radiomics analysis including 16 key components of which each is 
given a number of points corresponding to the importance of the respective 
component.86 Major check points in the RQS are data selection, medical imaging, 
features extraction, exploratory analysis, and modeling. The highest possible total RQS 
for quantification of the overall methodology and analysis of radiomics practice is 36 
points. Therefore, efforts should be made to consider RQS in future studies and to 
stablish collaborative foundations to control and fully realize the potential of radiomics.   
Another feature that may help in tumor response evaluation is delta 
radiomics.86,90 In contrast to most radiomics studies, which are based on features 
extracted at a single time point (usually at the time of diagnosis), delta radiomics 
evaluates changes in radiomics features between interval studies. Delta-radiomics 
features have shown potential in predicting response or survival in patients with 
colorectal cancer liver metastasis, metastatic renal cell, and lung cancer.90-92  According 
to a study of 107 NSCLC patients, pretreatment radiomics features were not prognostic, 
while texture-strength measured at the end of treatment significantly stratified high- and 
low-risk patients, thus suggesting the potential of delta-radiomics features.90 
Nevertheless, if delta radiomics were to be employed in clinical practice, standardization 
of technical factors and high reproducibility of the features remain prerequisites. 
In conclusion, compared to the current RECIST version 1.1, tumor volumetric 
measurement and radiomics are more quantitative measures and supplement the 
limitations of RECIST in the current era of precision cancer therapy. Nevertheless, 
substantial variability can be introduced in the process of measuring tumor burden due 
to various technical factors. Furthermore, the increasing role of software post- 
processing and radiomics support the need for increased awareness of technical factors 
of image acquisition among radiologists. We await the incorporation of these advanced 
image processing metrics of Radiomics and Artificial Intelligence into the new RECIST 
criteria for tumor response assessment. 
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Figure Legends 
Figure 1. Various methods of tumor segmentation. A) Part-solid adenocarcinoma with 
internal air-bronchogram at the right upper lobe. B) Automatic segmentation of the solid 
portion. C) Automatic segmentation of the ground glass opacity (GGO) portion. D) Semi-
automatic segmentation with subjective tumor margin editing demonstrates the final 
solid portion (blue) and GGO portion (red). 
 
Figure 2. Graph demonstrates the attenuation profile along a vertical line through the 
tumor. Tumor margins are assumed by the rapid slope of pixel values. The area of 
negative pixel values within the tumor suggests the presence of air-bronchogram.  
 
Figure 3. As part-solid adenocarcinoma, 5 mm slice images (top row) show less solid 
portion compared to 1.25 mm slice images (bottom row). Thicker-slice image contains 
larger partial volume artifacts than a thinner-slice image, thus influencing the true 
details of lung adenocarcinoma.  
 
Figure 4. The extended Tofts model. Assumption of this model is the equilibrium of the 
contrast agent between the plasma and extravascular extracellular space (EES) 
 
Figure 5. Difference in grey-level co-occurrence matrix  (GLCM) according to number of 
bins. The two GLCMs are from the same patient with different numbers of bins. The 
GLCMs are displayed using the same scale. The left figure has more bins thus can have 
fewer counts per bin, while the right figure has fewer bins and thus more counts per bin. 
These differences in counts per bin led to different features values of GLCM. 
 
Figure 6. Histogram samples for radiomics. A) 1D Histogram within ROI. In most cases, 
the analysis using CT images considers a full range of HU values (i.e., 4096 bins). B) 2D 
histogram of grey-level co-occurrence matrix (GLCM). The 2D histogram of GLCM is built 
using intensity of given voxel as the first axis and intensity of the neighboring voxel as 
the second axis. C) 2D histogram of intensity size zone matrix (ISZM). The horizontal 
axis denotes intensity, and the vertical axis denotes size of a given blob. 
 
Figure 7. Original image of lung cancer is enhanced by two different methods of Laplace 
of Gaussian. 
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Table Legends. 
Table 1. Dependence of gadolinium based contrast agent and 
Ferumoxytol relaxivity on field strength.82,83  
Short name or 
Internal Code 
Generic Name 
1.5T 3T 
R1 R2 R1 R2 
Gd-BOPTA Gadobenate 
dimeglumine 
6.0-6.6 7.8-9.6 5.2-5.8 10.0-12.0 
Gd-HP-DO3A Gadoteridol 3.9-4.3 4.2-5.8 3.5-3.9 4.8-6.6 
Gd-DO3A-butrol Gadobutrol 4.9-5.5 5.2-7.0 4.7-5.3 6.2-8.0 
Gd-DTPA Gadopentetate 
dimeglumine 
3.9-4.3 3.8-5.4  (3.5-3.9 4.3-6.1 
Gd-DOTA Gadoterate 
meglumine 
3.4-3.8 3.4-5.2 3.3-3.7 4.0-5.8 
Gd-DTPA-BMA Gadodiamide 4.0-4.6  4.2-6.2 3.8-4.2 4.7-6.5 
Code 7228* Ferumoxytol 17.3-20.7 63.1-66.7 9.3-9.7 63.4-67.0 
*Superparamagnetic iron oxide MR contrast agent 
 
 
 
 
 
 
 
Tables
Table 2. Variables of Tofts equation 
Quantity Definition Unit 
C(t) Tissue concentration as a function of time mM 
Ca(t) Concentration in plasma as a function of time mM 
Ktrans 
Transfer constant from the blood plasma into 
the EES 
mL/g/min 
Kep 
Transfer constant from the EES back to the 
blood plasma 
1/min 
vp Volume fraction of the plasma space none 
ve Volume fraction of the EES none 
EES = extravascular extracellular space 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Representative PET radiotracers for lung cancer 
PET radiotracers  Uptake mechanism Clinical utility 
FDG Tumor glucose 
metabolism 
Diagnosis, initial staging, detecting 
recurrence, and therapy response 
evaluation 
18F-Fluorothymidine Tumor cell proliferation Early therapy response evaluation 
18F-
fluoromisonidazole 
Tumor hypoxia Radiotherapy planning 
18F-alfatide Tumor angiogenesis Therapy response evaluation 
11C-PD153035, 11C-
erlotinib 
Tumor epidermal growth 
factor receptor (EGFR) 
Therapy response evaluation to EGFR–
tyrosine kinase inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Criteria of radiomics quality score (RQS) and 
corresponding points. 
Criteria Score 
Image protocol quality +1 or +2 
Multiple segmentation +1 
Phantom study +1 
Imaging at multiple time points +1 
Feature reduction or adjustment for multiple testing -3 or +3 
Multivariable analysis +1 
Biological correlates +1 
Cut-off analysis +1 
Discrimination statistics +1 or +2 
Calibration statistics +1 or +2 
Prospective study +7 
Validation -5 to +5 
Comparison to ‘gold standard’ +2 
Potential clinical applications +2 
Cost-effectiveness analysis +1 
Open science and data +1 to +4 
RQS total 36 
 
 
 
 
 
 
 
